ReviewJournal of ophthalmology2014
Sustained-release corticosteroid options.
Review in Journal of ophthalmology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials.Drug design, development and therapy · 2019Pooled it
- Efficacy and safety of different doses of a slow-release corticosteroid implant for macular edema: meta-analysis of randomized controlled trials.Drug design, development and therapy · 2015Pooled it
- Treatment of ocular sarcoidosis. Study of 65 patients from a series of 342 from a university hospital in northern Spain.International ophthalmology · 2025Article
- Incident glaucoma and ocular hypertension after periocular and intravitreal steroid injections: a claims-based analysis.BMJ open ophthalmology · 2023Article
- Pathogenesis and current therapies for non-infectious uveitis.Clinical and experimental medicine · 2023Review
- Treatment of Non-Infectious Posterior Uveitis with Dexamethasone Intravitreal Implants in a Real-World Setting.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Intravitreal fluocinolone acetonide 0.19 mg (Iluvien®) for the treatment of uveitic macular edema: 2-year follow-up of 20 patients.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Article
- Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis.Journal of clinical medicine · 2021Article
- Uveitic macular edema response to intravitreal dexamethasone implant is independent of optical coherence tomography findings.International ophthalmology · 2021Article
- Saudi Arabia Guidelines for diabetic macular edema: A consensus of the Saudi Retina Group.Saudi medical journal · 2021Article
- Sustained Control from Recurring Non-Infectious Uveitic Macular Edema with 0.19 mg Fluocinolone Acetonide Intravitreal Implant - A Case Report.Ophthalmology and therapy · 2019Article
- Extended release of dexamethasone from oleogel based rods.Journal of colloid and interface science · 2019Article
- Management of chronic ocular sarcoidosis: challenges and solutions.Clinical ophthalmology (Auckland, N.Z.) · 2018Review
- New Drugs and New Posterior Delivery Methods in CME.Current ophthalmology reports · 2017Article
- Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.Journal of controlled release : official journal of the Controlled Release Society · 2017Review
- Simultaneous dexamethasone intravitreal implant and anti-VEGF therapy for neovascular age-related macular degeneration resistant to anti-VEGF monotherapy.Journal of vitreoretinal diseases · 2017Article
- Ocular Complications of Diabetes and Therapeutic Approaches.BioMed research international · 2016Review
- Effect of dexamethasone intravitreal implant in a corneal graft rejection.International journal of ophthalmology · 2016Article
- Efficacy and safety of different doses of a slow release corticosteroid implant for macular edema.Drug design, development and therapy · 2016Article
- Fluocinolone Implant Forceps: Instrument Modification for Enhanced Implant Insertion.International ophthalmology clinics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sustained-release corticosteroid treatment has shown to be a promising strategy for macular edema due to retinovascular disease (i.e., diabetes and retinal vein occlusion) and for the treatment of noninfectious posterior uveitis. Clinicians now have the option of three sustained-release corticosteroid implants: Ozurdex (Allergan Inc., Irvine, CA) which releases dexamethasone and two devices that release fluocinolone acetonide, Retisert (Bausch & Lomb, Rochester, NY), and Iluvien (Alimera Science, Alpharetta, GA). Each has different physical characteristics and duration effect and has been approved for different indications. Herein we provide a summary of the current clinical knowledge regarding these implants.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.